콘텐츠로 건너뛰기
Merck
  • Environmental impact assessment of pharmaceutical prescriptions: Does location matter?

Environmental impact assessment of pharmaceutical prescriptions: Does location matter?

Chemosphere (2014-02-11)
Rik Oldenkamp, Mark A J Huijbregts, Anne Hollander, Ad M J Ragas
초록

A methodology was developed for the assessment and comparison of the environmental impact of two alternative pharmaceutical prescriptions. This methodology provides physicians with the opportunity to include environmental considerations in their choice of prescription. A case study with the two antibiotics ciprofloxacin and levofloxacin at three locations throughout Europe showed that the preference for a pharmaceutical might show spatial variation, i.e. comparison of two pharmaceuticals might yield different results when prescribed at different locations. This holds when the comparison is based on both the impact on the aquatic environment and the impact on human health. The relative impacts of ciprofloxacin and levofloxacin on human health were largely determined by the local handling of secondary sludge, agricultural disposal practices, the extent of secondary sewage treatment, and local food consumption patterns. The relative impacts of ciprofloxacin and levofloxacin on the aquatic environment were mostly explained by the presence of specific sewage treatment techniques, as effluents from sewage treatment plants (STPs) are the most relevant emission pathway for the aquatic environment.

MATERIALS
제품 번호
브랜드
제품 설명

Supelco
Ciprofloxacin HCl, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Ciprofloxacin, VETRANAL®, analytical standard
Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
Supelco
Ciprofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Ciprofloxacin hydrochloride, United States Pharmacopeia (USP) Reference Standard
Ciprofloxacin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Ciprofloxacin, European Pharmacopoeia (EP) Reference Standard
Ciprofloxacin hydrochloride for peak identification, European Pharmacopoeia (EP) Reference Standard